NorthWest Biotherapeutics Inc (NWBO)

[HyGro]

Dr. Liau chose PFS as the primary endpoint in the SPORE/UCLA trial so the technology is clearly valid or she wouldn't use it again. Clearly she believes in PFS as her primary endpoint. For DCVax-L trial her interim analysis made it obvious that DCVax-L was NOT going to meet the primary endpoint. NWBO's future (and Dr. Liau's) was absolutely dependent on meeting the endpoint and they were desperate. Two weeks before the end of the they totally redid the trial protocol -- new endpoint, new trial arm, new comparator.

It's the facts.